Market Gems:Stocks w/Strong Earnings and High Tech. Rank Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Barbara B who wrote (18416)	11/11/1998 9:53:00 AM
From: Jenna	Read Replies (1) of 120523

moving well: TJX,FRED,TWMC,OMPT,MDM... out FOSL.. ANF still a good buy at 50 could climb higher intraday November 10 article: but stock still running: VYSI..DOWNERS GROVE, Ill. (CBS.MW) -- Shares of Vysis Inc. launched 30 percent Tuesday after a Food and Drug Administration committee panel approved its product that helps find breast cancer genes. Vysis' (VYSI) PathVysion HER-2 DNA kit helps detect the HER-2 gene in women. The company said if women have "abnormally high" amounts of the gene, it can speed up cancerous cells, resist therapy for tumors and eventually cut the life span of women with breast cancer. "The is the first time the most appropriate treatment will be based on the genetic composition of a patient," said John Bishop, Vysis' chief executive. It will allow therapy to be more precise, he said. Vysis said the gene "plays a pivotal role" in 25 percent to 30 percent of women with breast cancer. The FDA could approve the sale of the test in as little as 30 days, Bishop said.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next